Until recently, in contrast to psoriasis vulgaris, no biologics were available for the treatment of atopic dermatitis, therefore the therapeutic options, especially in severe cases and lack of response to the only approved systemic therapy with ciclosporin A, were very limited. Dupilumab was approved in January 2018 as the first biologic for the treatment of atopic dermatitis. This is a fully human monoclonal antibody to the alpha subunit of the interleukin (IL)-4 receptor, thereby inhibiting IL-4/IL-13 signaling pathways. Here we describe the case of a 46-year-old asian patient with severe refractory atopic dermatitis as well as with secondary diagnosed eosinophilic pustular folliculitis and the course of his disease under therapy with dupilumab.